Entero-Logo-Options-FINAL.png
First Wave BioPharma Changes Name to Entero Therapeutics
May 16, 2024 07:00 ET | Entero Therapeutics, Inc.
Rebranding introduced as Company advances toward Phase 3 clinical trial with lead asset – latiglutenase for the treatment of celiac disease New Nasdaq ticker symbol is “ENTO” effective May 17, 2024 ...
First-Wave-Logo-FINAL-RGB[1].jpg
First Wave BioPharma and Celiac Journey to Host Nasdaq Event in Support of Celiac Disease Awareness Month
May 09, 2024 07:00 ET | First Wave BioPharma, Inc.
BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...